PR88911

Shanghai Genechem Co., Ltd. (Genechem) Announces appointment of Dr. Eric Rowinsky and Dr. Manuel Hidalgo to Scientific Advisory board, and abstract presentation at AACR 2021 on Claudin 6 Ab and K-Ras TCR-T

SHANGHAI, April 8, 2021 /PRNewswire=KYODO JBN/ --

Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel

target discovery and development of novel therapeutics, today announced the

appointment of Dr. Eric Rowinsky, President and Executive Chairman of the Board

of Rgenix, Inc., and Dr. Manuel Hidalgo, Chief of Hematology and Medical

Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell

Medical Center, to its Scientific Advisory Board. Drs. Rowinsky and Hidalgo

will bring their strong expertise in translational and clinical development to

support Genechem's mission to bring its innovative pipeline to global markets

through novel target discovery, early development in China, and global

partnership.

Genechem also announces that it will present two abstracts at AACR 2021, on an

antibody against Claudin 6, and a TCR-T therapy against K-Ras mutations.  

(https://www.abstractsonline.com/pp8/#!/9325/presentation/2600,

https://www.abstractsonline.com/pp8/#!/9325/presentation/1949)

"We are excited to welcome Drs. Rowinsky and Hidalgo, global leaders in

biopharma industry and translational/clinical development, to our SAB, as we

position Genechem to collaborate with cancer centers and biopharmaceutical

companies globally to advance development of its innovative pipeline developed

on our Good Research Practice (GRP) platform, leveraging CHAMP antibody

discovery platform and Cell Therapy Discovery platform", commented Yueqiong

Cao, Founder and CEO of Genechem.

"Genechem has built an innovative preclinical pipeline over the last five

years, building on almost 20 years of partnership with research Oncologists in

China, and I look forward to contributing my expertise to their mission of

bringing innovative medicine to patients and partners globally. I am also

impressed by their vision and global caliber management team, which I will

enjoy working with", Dr. Rowinsky remarked.

Dr. Rowinsky is currently serving on the Board of Directors for Biogen and as

President and Executive Chairman of RGenix, Inc. Dr. Rowinsky has also been the

Chief Scientific Officer of Clearpath Development Co., which rapidly advances

development stage therapeutic assets to pre-defined human proof-of-concept

milestones. Dr. Rowinsky was the Head of Research and Development and Chief

Medical Officer of Stemline Therapeutics, Inc., a biotechnology company

focusing on the discovery and development of therapeutics targeting cancer stem

cells. Dr. Rowinsky has also been an Adjunct Professor of Medicine at New York

University and has been an independent consultant from 2010-2019. Prior to

that, he was the Chief Executive  Officer of Primrose Therapeutics, Inc., a

start-up biotechnology company focusing on the development of therapeutics for

polycystic kidney disease. From 2005 to December 2009 he served as the Chief

Medical Officer and Executive Vice President of ImClone Systems Incorporated, a

life sciences company. From 1996 to 2004 Dr. Rowinsky held several positions at

the Cancer Therapy & Research Center's Institute for Drug Development,

including Director of the Institute and Director of Clinical Research. During

that time, he held the SBC Endowed Chair for Early Drug Development and was

Clinical Professor of Medicine at the University of Texas Health Science Center

at San Antonio. From 1988 to 1996 Dr. Rowinsky was an associate professor of

oncology at the Johns Hopkins School of Medicine and on the staff of the Johns

Hopkins Hospital. Dr. Rowinsky is also a member of the Boards of Directors of

Fortress Biotech Inc., Purple Biotech Ltd. and Verastem, Inc., all of which are

biopharmaceutical companies.

"As a clinical oncologist involved in drug discovery and clinical trials, I'm

excited to bring my expertise to Genechem and help advance its antibody and

cell therapy platforms. I am pleased to support Genechem's global efforts in

advancing scientific understanding of cancer and addressing clinical unmet

needs, in particular in solid tumors," said Dr. Hidalgo, who receives an

honorarium for participation on Genechem's SAB.

Manuel Hidalgo, M.D., Ph.D.is currently the Chief of the Division of Hematology

and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill

Cornell Medical Center. He is also the Hugh E. Luckey Distinguished Professor

of Medicine and a senior member of the Sandra and Edward Meyer Cancer Center at

Weill Cornell Medicine. Dr. Hidalgo received his MD degree from the University

of Navarra in Pamplona, Spain in 1992 and a Ph.D. degree from University

Autonoma of Madrid in 1997. He trained in medicine and medical oncology at

Hospital ¨12 de Octubre¨ in Madrid and at the University of Texas Health

Science Center in San Antonio. He also completed a fellowship program in

anticancer drug development at the Institute of Drug Development in San

Antonio, TX. Prior to this position he served as an Assistant Professor of

Medicine at the Division of Hematology and Oncology at the University of Texas

Health Science Center in San Antonio. In 2001, Dr. Hidalgo relocated to Johns

Hopkins University to be Director of the Gastrointestinal Oncology Program at

the Kimmel Comprehensive Cancer Center at Johns Hopkins and Associate Professor

of Oncology. In 2009 he became Director of the Clinical Research Program at the

Spanish National Cancer Center and Vice director of Translational Research in

2011. In 2015 he became the Chief of the Division of Hematology and Oncology

and Director of the Rosenberg Clinical Cancer Center at the Beth Israel

Deaconess Medical Center in Boston. He was also the Theodore W. and Evenly G.

Berenson Professor of Medicine at Harvard Medical School. His main focus of

research has been new drug development in pancreatic cancer. His group

popularized the use of Avatar mouse models for cancer research and recently

contributed to the development and approval of nab-paclitaxel for pancreatic

cancer treatment. His current work focuses on strategies for personalized

medicine and immunotherapy in pancreatic cancer.

About Shanghai Genechem Co., Ltd. (Genechem)

Genechem is a leading innovation research company focused on target

discovery/validation, development of antibody and cell therapy products against

novel targets, and partnership globally to maximize its portfolio. Founded in

2002, now with over 500 employees, Genechem works closely with Research

Oncologists to translate clinical research into therapeutics addressing high

clinical unmet needs, leveraging its strong network of Research Oncologists in

over 300 hospitals and Good Research Practice (GRP platform) which includes

comprehensive RNAi library, tools including genetic typing, bioinformatic

analysis, genetic manipulation, as well as SOP and project management systems.

For more information, visit http://www.gcbio.com/.

Contact:

Dr. Tong Zhang

Chief Business Officer

Shanghai Genechem Co., Ltd

Tong.zhang@genechem.com.cn

+86-18501607878

SOURCE  Shanghai Genechem Co., Ltd. (Genechem)